Home Featured Page 203

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access...

Trauma and Vulnerability to Suggestion: Redefining How We Understand Consent

COMPASS Pathways plc to announce fourth quarter and full year 2021...

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through...

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access...

Trauma and Vulnerability to Suggestion: Redefining How We Understand Consent

COMPASS Pathways plc to announce fourth quarter and full year 2021...

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through...

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY